Elanco’s Zenrelia™ Study Shows Promising Results in Dogs
Company Announcements

Elanco’s Zenrelia™ Study Shows Promising Results in Dogs

Elanco Animal Health ( (ELAN) ) has shared an update.

Elanco Animal Health presented findings at an ISCAID symposium showing that their novel JAK inhibitor, Zenrelia™, didn’t alter serologic responses in dogs after booster vaccinations. The study, involving young Beagle dogs, found no significant differences in protective titers between treated and control groups, with no serious adverse events. Zenrelia™ has also gained approval in Canada.

For a thorough assessment of ELAN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyElanco price target lowered to $19 from $22 at Barclays
Joseph E. LeviInvestors in Elanco Animal Health Incorporated Should Contact Levi & Korsinsky LLP Before December 06, 2024 to Discuss Your Rights – ELAN
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App